BioCentury
ARTICLE | Clinical News

Prolastin-C: Phase II started

December 20, 2010 8:00 AM UTC

Talecris began the double-blind, crossover, U.S. Phase II SPARK trial to compare 60 and 120 mg/kg doses of weekly IV Prolastin-C for 8 weeks in 30 patients. The 60 mg/kg dose is already approved to tr...